Mckesson Stock Earnings Reports

McKesson reported a strong start to fiscal 2026: consolidated revenue of $97.8 billion (up 23%) and adjusted operating profit of $1.4 billion (up 9%). Management raised full‑year adjusted EPS guidance to $37.10–$37.90. Key drivers were growth in the U.S. Pharmaceutical segment (including GLP‑1 volumes of $12.1 billion, +38% YoY), double‑digit operating profit growth in three of four segments, solid performance at Prescription Technology Solutions (RxTS), and contributions from the recent acquisitions of PRISM Vision and Core Ventures. McKesson is continuing portfolio actions: announced intent to spin off Medical‑Surgical into an independent company and entered a definitive agreement to sell its Norway retail and distribution businesses (which will be classified as held‑for‑sale and is estimated to add ~ $0.20 to adjusted EPS via held‑for‑sale accounting; guidance assumes the deal does not close in fiscal 2026). Management highlighted ongoing investments in automation and cold‑chain capabilities (noting measurable operating leverage and productivity gains), expanding oncology and biopharma services, and a focus on employee and community initiatives. Cash and capital deployment: quarter end cash $2.4B, negative free cash flow of $1.1B in Q1 (included $3.4B used for acquisitions), completed $2B bond issuance, returned $671M to shareholders (including $581M buybacks), board approved a 15% dividend increase, and management expects roughly $4.4–$4.8B free cash flow for the year with ~$2.5B in share repurchases planned. Guidance summary: revenue growth 11–15% and operating profit growth 9–13% for fiscal 2026, with segment-level detail showing continued strong expectations for U.S. Pharmaceutical and RxTS.